Physicians' Academy for Cardiovascular Education

When and how to initiate SGLT2i in CKD

4 things to know about CKD and SGLT2i - lecture 2 out of 4

Listen to the podcast
10' education - Feb. 14, 2023 - Prof. David Wheeler, MD - London, UK

Video navigation menu

  • SGLT2i trials in CKD 00:35
  • Case 1: type 2 diabetes and CKD 01:46
  • Practical issues for nephrologists prescribing SGLT2i : ketoacidosis 03:54
  • Case 2: progressive IgA nephropathy 05:57
  • Case 3: ischemic nephropathy 07:14
  • Practical issues for nephrologists prescribing SGLT2i : acute decline in eGFR 10:19
  • Practical issues for nephrologists prescribing SGLT2i : volume depletion 11:12
  • Take home messages 12:17

In general, do you feel comfortable prescribing SGLT2i to patients with CKD?

  • Yes
  • No, often due to worries about risk of ketoacidosis, acute decline in eGFR or volume depletion
  • No, due to other reasons


Show transcript

Educational information

This educational video is part of a series called '4 Things to know about CKD and SGLT2i'.


Prof. David Wheeler is Professor of Kidney Medicine at University College London, UK.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from AstraZeneca.

Watch the first lecture of this series

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: